Acute leukaemia, Acute myeloid leukaemia (AML), Blood cancers, Leukaemia
Results
Phase 3
This trial looked at adding venetoclax to low dose cytarabine for acute myeloid leukaemia (AML).
It was for people who:
hadn’t had treatment and
weren’t suitable to have intensive chemotherapy to get rid of the AML
This trial was open for people to join between 2017 and 2018. The team published the results in 2020.
Recruitment start: 1 December 2017
Recruitment end: 2 May 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Caroline Alvares
AbbVie
Last reviewed: 8 March 2022
CRUK internal database number: 15218
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
